Portfolio company Eclipsebio acquired Terrain Bio to expand its RNA therapeutics platform.
Terrain Bio develops an AI-driven platform for designing and producing RNA molecules, accelerating therapeutics and vaccines
Terrain Bio develops an AI-driven platform for designing and producing RNA molecules, accelerating therapeutics and vaccines. It engineers RNA with improved stability, efficacy, and manufacturability for diverse uses.